Latest Schedule 13G passive stakes

Armistice Capital, LLC and Steven Boyd have jointly filed a Schedule 13G, disclosing beneficial ownership of 9.88% of Kyntra Bio, Inc.'s common stock.

Armistice Capital, LLC and Steven Boyd have filed a Schedule 13G, reporting beneficial ownership of 120,537 shares of INVO FERTILITY, INC. common stock, representing 4.99% of the class.

Armistice Capital, LLC and Steven Boyd have reported a beneficial ownership of 13,932,000 shares, representing 8.43% of Ironwood Pharmaceuticals, Inc.'s Class A common stock.

Armistice Capital, LLC, along with its managing member Steven Boyd, has reported beneficial ownership of 9.99% of Inuvo, Inc.'s common stock as of June 30, 2026.

Armistice Capital, LLC and Steven Boyd have jointly filed a Schedule 13G, reporting beneficial ownership of 141,397 shares, representing 5.91% of Intelligent Bio Solutions Inc.'s common stock.

Aristeia Capital, L.L.C. has disclosed a beneficial ownership of 900,000 units, representing 5.22% of the outstanding shares in JAB Acquisition Corp I.

Armistice Capital, LLC and Steven Boyd have filed a Schedule 13G, reporting beneficial ownership of 450,315 shares, representing 9.99% of Imunon, Inc.'s common stock.

Aristeia Capital, L.L.C. has disclosed beneficial ownership of 5.24% of Maywood Acquisition Corp.'s Class A Ordinary Shares.

Armistice Capital, LLC and Steven Boyd have jointly reported beneficial ownership of 300,332 ordinary shares, representing 9.99% of IceCure Medical Ltd., as of June 30, 2026.

Eric M. Mindich has updated his beneficial ownership in Blue Moon Metals Inc. to 3.5% as of June 30, 2026, based on the latest outstanding share count.

Aristeia Capital, L.L.C. has reported beneficial ownership of 1,315,573 Class A ordinary shares, representing 5.20% of the outstanding shares of Inflection Point Acquisition Corp. VI.

Armistice Capital, LLC and Steven Boyd have reported beneficial ownership of 387,038 shares, representing 4.99% of GeoVax Labs, Inc. common stock.

Ameriprise Financial and Columbia Management report a combined 6.3% beneficial ownership of Diversified Energy Company common stock.

Ameriprise Financial and Columbia Management report a combined 6.3% beneficial ownership of Diversified Energy Company common stock.

Armistice Capital, LLC and Steven Boyd have jointly reported beneficial ownership of 9.99% of Global Interactive Technologies, Inc. common stock.

Aristeia Capital, L.L.C. has filed a Schedule 13G, reporting beneficial ownership of 4,840,477 shares of Hadron Energy, Inc. common stock, representing 6.59% of the outstanding shares.

Armistice Capital, LLC and Steven Boyd have jointly filed a Schedule 13G, reporting beneficial ownership of 9.99% of Generation Income Properties, Inc. common stock as of June 30, 2026.

Aristeia Capital, L.L.C. has filed a Schedule 13G, disclosing beneficial ownership of 2,203,396 warrants in OppFi Inc., representing 2.52% of the class.

Aristeia Capital, L.L.C. has filed a Schedule 13G, revealing beneficial ownership of 652,725 units in FortuneX Acquisition Corporation, representing approximately 7.55% of the outstanding securities.

Armistice Capital, LLC and Steven Boyd report acquiring a 9.99% beneficial ownership in FibroBiologics, Inc. common stock.

Armistice Capital, LLC and Steven Boyd have jointly filed a Schedule 13G, reporting beneficial ownership of 713,539 ordinary shares, representing 4.99% of Evogene Ltd.'s outstanding shares.

Aristeia Capital, L.L.C. has disclosed beneficial ownership of 1,350,000 units, representing 5.30% of Praetorian Acquisition Corp.'s outstanding shares as of June 30, 2026.

Aristeia Capital, L.L.C. has disclosed a beneficial ownership of 2,178,000 units, representing 8.61% of the outstanding shares of Collective Acquisition Corp. II.

Armistice Capital, LLC and Steven Boyd have filed a Schedule 13G, reporting beneficial ownership of 4.99% of Estrella Immunopharma, Inc. common stock.

Armistice Capital, LLC and Steven Boyd have jointly filed a Schedule 13G, disclosing beneficial ownership of 9.99% of Enveric Biosciences, Inc. common stock.

Aristeia Capital, L.L.C. has filed a Schedule 13G, reporting beneficial ownership of 7.99% of ClearThink 1 Acquisition Corp.'s Class A ordinary shares as of June 30, 2026.

Armistice Capital, LLC and Steven Boyd have jointly filed a Schedule 13G, reporting beneficial ownership of 3,384,798 shares, representing 9.99% of Dogwood Therapeutics, Inc.'s common stock.

Ameriprise Financial, Inc. and its subsidiaries, Columbia Management Investment Advisers, LLC and Columbia Small Cap Value Discovery Fund, have reported a combined beneficial ownership of 8.1% in Universal Electronics Inc. as of June 30, 2026.

Ameriprise Financial, Inc. and its subsidiaries, Columbia Management Investment Advisers, LLC and Columbia Small Cap Value Discovery Fund, have reported a combined beneficial ownership of 8.1% in Universal Electronics Inc. as of June 30, 2026.

Armistice Capital, LLC, through its Master Fund, has acquired a 9.99% stake in Decoy Therapeutics Inc., signaling a notable investment in the company's common stock.